{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:24:38Z","timestamp":1794709478640,"version":"4.9.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000008404","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T22:05:35Z","timestamp":1511906735000},"page":"e8404","source":"Crossref","is-referenced-by-count":28,"title":["The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases"],"prefix":"10.1097","volume":"96","author":[{"given":"Enda J.","family":"Hannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"MacNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine W.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm P.","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold D.K.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210226","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-8-20210226","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"R4-8-20210226","first-page":"874","article-title":"Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ & the US) study","volume":"23","author":"Carlino","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"R5-8-20210226","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1586\/ern.10.30","article-title":"Brain metastases: a medical neuro-oncology perspective","volume":"10","author":"Chamberlain","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R6-8-20210226","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0360-3016(98)00442-8","article-title":"Identification of prognostic factors in patients with brain metastases: a review of 1292 patients","volume":"43","author":"Lagerwaard","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-8-20210226","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-8-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CMR.0b013e328352dbef","article-title":"Melanoma in the brain: biology and therapeutic options","volume":"22","author":"Gibney","year":"2012","journal-title":"Melanoma Res"},{"key":"R9-8-20210226","doi-asserted-by":"crossref","first-page":"505","DOI":"10.6004\/jnccn.2008.0038","article-title":"Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy","volume":"6","author":"Ewend","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-8-20210226","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC)","volume":"35","author":"Long","year":"2017","journal-title":"J Clin Oncol"},{"key":"R11-8-20210226","first-page":"1775","article-title":"Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies","volume":"5","author":"Sithanandam","year":"1990","journal-title":"Oncogene"},{"key":"R12-8-20210226","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R13-8-20210226","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrm1498","article-title":"The RAF proteins take centre stage","volume":"5","author":"Wellbrock","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R14-8-20210226","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-8-20210226","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-8-20210226","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"R17-8-20210226","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(17)30449-7","article-title":"BRAF-MEK inhibition in melanoma brain metastases: a new hope","volume":"18","author":"Forsyth","year":"2017","journal-title":"Lancet Oncol"},{"key":"R18-8-20210226","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PAS.0b013e318271249e","article-title":"Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions","volume":"37","author":"Busam","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R19-8-20210226","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"key":"R20-8-20210226","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, Phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"R21-8-20210226","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"R22-8-20210226","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"R23-8-20210226","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/1097-0142(19821015)50:8<1656::AID-CNCR2820500833>3.0.CO;2-L","article-title":"The natural history of resectable metastatic melanoma (stage IVA melanoma)","volume":"50","author":"Feun","year":"1982","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:37:56Z","timestamp":1620959876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712010-00008"}},"subtitle":["The implications for BRAF inhibitor therapy"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":22,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008404","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}